DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07276763

Not yet recruiting

Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention

Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention: A Retrospective Observational Study

Lead sponsor

Fudan University

Assets

Dulaglutide / Semaglutide

Listed sites

1

Recruiting sites

—

Enrollment

16,509

estimated

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Proportion of gastric retention

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07276763
Org study ID2025K368

Timeline

Milestones

Study start2025-12-10estimated
Study first posted2025-12-11actual
Last update posted2025-12-11actual
Primary completion2025-12-15estimated
Study completion2025-12-15estimated

Assets

Investigational agents

DulaglutideSemaglutide

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

All patients who underwent elective EGD at Huadong Hospital and had complete retrievable information on medication use, medical records, and endoscopy reports

Inclusion criteria

•Undergoing elective upper endoscopy
•Complete clinical information available, including endoscopy report, age, sex, BMI, history of diabetes, prior gastric surgery, and gastrointestinal symptom

Exclusion criteria

•Presence of upper gastrointestinal malignancy or obstruction
•History of gastric surgery (including ESD, gastrectomy, gastric bypass, etc.)
•Emergency endoscopy or non-elective procedures
•Missing key clinical information

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

1 endpoint
Primary/protocol endpoint

Proportion of gastric retention

Time frame:Immediately at study initiation

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.